References
- Sharma P , AllisonJP . Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential . Cell161 ( 2 ), 205 – 214 ( 2015 ).
- Brahmer JR , TykodiSS , ChowLQet al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer . N. Engl. J. Med.366 ( 26 ), 2455 – 2465 ( 2012 ).
- Topalian SL , HodiFS , BrahmerJRet al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer . N. Engl. J. Med.366 ( 26 ), 2443 – 2454 ( 2012 ).
- Adams JL , SmothersJ , SrinivasanR , HoosA . Big opportunities for small molecules in immuno-oncology . Nat. Rev. Drug Discov.14 ( 9 ), 603 – 622 ( 2015 ).
- Zitvogel L , GalluzziL , SmythMJ , KroemerG . Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance . Immunity39 ( 1 ), 74 – 88 ( 2013 ).
- Melero I , BermanDM , AznarMA , KormanAJ , Perez GraciaJL , HaanenJ . Evolving synergistic combinations of targeted immunotherapies to combat cancer . Nat. Rev. Cancer15 ( 8 ), 457 – 472 ( 2015 ).
- Ji RR , ChasalowSD , WangLet al. An immune-active tumor microenvironment favors clinical response to ipilimumab . Cancer Immunol. Immunother.61 ( 7 ), 1019 – 1031 ( 2012 ).
- Herbst RS , SoriaJC , KowanetzMet al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients . Nature515 ( 7528 ), 563 – 567 ( 2014 ).
- Zheng H , ZhaoW , YanCet al. HDAC inhibitors enhance T cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma . Clin. Cancer Res. doi:10.1158/1078-0432.CCR-15-2584 ( 2016 ) ( Epub ahead of print ).
- Hopewell EL , ZhaoW , FulpWJet al. Lung tumor NF-kappaB signaling promotes T cell-mediated immune surveillance . J. Clin. Invest.123 ( 6 ), 2509 – 2522 ( 2013 ).
- Ma T , GalimbertiF , ErkmenCPet al. Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer . Mol. Cancer Ther.12 ( 8 ), 1545 – 1555 ( 2013 ).
- Burke SJ , GoffMR , LuD , ProudD , KarlstadMD , CollierJJ . Synergistic expression of the CXCL10 gene in response to IL-1beta and IFN-gamma involves NF-kappaB, phosphorylation of STAT1 at Tyr701, and acetylation of histones H3 and H4 . J. Immunol.191 ( 1 ), 323 – 336 ( 2013 ).
- Kim K , SkoraAD , LiZet al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells . Proc. Natl Acad. Sci. USA111 ( 32 ), 11774 – 11779 ( 2014 ).
- Vo DD , PrinsRM , BegleyJLet al. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824 . Cancer Res.69 ( 22 ), 8693 – 8699 ( 2009 ).
- Christiansen AJ , WestA , BanksKMet al. Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies . Proc. Natl Acad. Sci. USA108 ( 10 ), 4141 – 4146 ( 2011 ).
- West AC , MattarolloSR , ShorttJet al. An intact immune system is required for the anticancer activities of histone deacetylase inhibitors . Cancer Res.73 ( 24 ), 7265 – 7276 ( 2013 ).
- West AC , JohnstoneRW . New and emerging HDAC inhibitors for cancer treatment . J. Clin. Invest.124 ( 1 ), 30 – 39 ( 2014 ).
- Peng D , KryczekI , NagarshethNet al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy . Nature527 ( 7577 ), 249 – 253 ( 2015 ).
- Tumeh PC , HarviewCL , YearleyJHet al. PD-1 blockade induces responses by inhibiting adaptive immune resistance . Nature515 ( 7528 ), 568 – 571 ( 2014 ).
- Schabath MB , WelshEA , FulpWJet al. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma . Oncogene doi:10.1038/onc.2015.375 ( 2015 ) ( Epub ahead of print ).